Trial Profile
An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2015
Price :
$35
*
At a glance
- Drugs Latrepirdine (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Medivation
- 09 Dec 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 17 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Apr 2009 Planned number of patients changed from 20 to 21 as reported by ClinicalTrials.gov.